CMS modified NCD 28 governing drug abuse treatment coverage, effective January 9, 2026. Here's what billing teams need to know before submitting claims.

The Centers for Medicare & Medicaid Services updated NCD 28 in the Medicare system, the National Coverage Determination that governs inpatient and outpatient hospital coverage for drug abuse (chemical dependency) treatment. This policy covers detoxification and rehabilitation services provided in hospital settings — both inpatient and outpatient departments. No specific CPT or HCPCS codes are listed in this policy document, which creates real documentation and adjudication challenges your billing team needs to understand now.


Quick-Reference Table

Field Detail
Payer CMS (Medicare)
Policy Treatment of Drug Abuse (Chemical Dependency)
Policy Code NCD 28
Change Type Modified
Effective Date January 9, 2026
Impact Level Medium
Specialties Affected Behavioral health, addiction medicine, hospital outpatient departments, inpatient facilities
Key Action Review medical necessity documentation for all drug abuse detox and rehab claims; confirm MAC-specific requirements before billing

CMS Drug Abuse Treatment Coverage Criteria and Medical Necessity Requirements 2026

The CMS drug abuse treatment coverage policy under NCD 28 covers two distinct care settings. Inpatient hospital care is covered when it is medically necessary for a patient to receive detoxification and/or rehabilitation for drug substance abuse. Outpatient hospital department services are also covered — specifically for patients discharged from an inpatient stay for drug substance abuse treatment, or for patients who need treatment but don't require the intensity of an inpatient setting.

That distinction matters for drug abuse treatment billing. CMS explicitly ties outpatient coverage to the same rules that govern all outpatient hospital services. That's a reference to the Medicare Benefit Policy Manual, Chapter 6, §20. If your team bills outpatient drug abuse treatment services, those billing guidelines apply directly to your claims.

Medical necessity is the linchpin here. CMS states that services must be reasonable and necessary for treatment of the individual's condition — a direct reference to the Medicare BPM, Chapter 16, §90 on general exclusions from coverage. The A/B Medicare Administrative Contractors (MACs) make medical necessity determinations based on accepted medical practice, with input from their medical consultants. Your MAC controls whether a claim for inpatient detox or outpatient rehab gets paid or denied.

There's a wrinkle. When a hospital is under Quality Improvement Organization (QIO) review, the QIO's medical necessity determinations are binding on A/B MACs for claims adjudication. If your facility operates under QIO oversight, the QIO's call on medical necessity — not your MAC's — drives reimbursement outcomes. Make sure your compliance officer knows which review entity applies to your facility.

The policy also notes that treatment intensity and duration for drug abuse may vary depending on the specific substance, how long the patient has been using, and the patient's medical and emotional condition. CMS draws an explicit parallel to alcohol detoxification and rehabilitation but acknowledges drug abuse treatment is not identical. This means there's no fixed length-of-stay rule baked into the NCD. MAC reviewers exercise clinical judgment, and so does QIO review. Your documentation needs to justify the specific duration and setting chosen for each patient.

The CMS drug abuse treatment coverage policy does not specify prior authorization requirements at the NCD level. However, that doesn't mean prior auth is off the table. Your MAC may have local coverage determination requirements, or your facility may be subject to Utilization Management review that functions similarly to prior authorization. Check with your MAC before assuming no prior auth is needed, especially for inpatient admissions.


Coverage Indications at a Glance

Indication Status Relevant Codes Notes
Inpatient hospital detoxification for drug substance abuse Covered Not specified in NCD 28 Must be medically necessary; MAC or QIO determines necessity
Inpatient hospital rehabilitation for drug substance abuse Covered Not specified in NCD 28 Must be medically necessary; MAC or QIO determines necessity
Outpatient hospital treatment following inpatient discharge for drug abuse Covered Not specified in NCD 28 Subject to outpatient hospital billing guidelines (BPM Ch. 6, §20)
+ 2 more indications

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

This policy is now in effect (since 2026-03-12). Verify your claims match the updated criteria above.

CMS Drug Abuse Treatment Billing Guidelines and Action Items 2026

The absence of specific CPT or HCPCS codes in NCD 28 is itself the biggest billing challenge this policy update creates. Here's how your team should respond before and after the January 9, 2026 effective date.

#Action Item
1

Contact your A/B MAC now. Because NCD 28 delegates medical necessity determinations to MACs, your MAC's local coverage determination or billing guidelines will govern claim approval. Call or check your MAC's website for any LCD tied to drug abuse treatment services. Don't assume the NCD alone is enough guidance.

2

Audit your medical necessity documentation for every drug abuse claim. CMS requires that services be reasonable and necessary for the specific patient's condition. Your clinical documentation must justify the care setting (inpatient vs. outpatient), the duration of treatment, and the intensity of services based on the substance involved, duration of use, and the patient's medical and emotional status. Thin documentation means high claim denial risk.

3

Determine whether your facility is under QIO review. If your hospital is subject to Quality Improvement Organization oversight, QIO determinations on medical necessity are binding on your MAC. Your billing team and compliance officer need to know this. A MAC-level approval or denial doesn't override a QIO decision when QIO review applies.

+ 3 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

Sample Version Diff Line-by-line changes
Previous VersionCurrent Version
Coverage is considered experimental and investigational for all indicationsCoverage is considered medically necessary when specific criteria are met
Prior authorization is not requiredPrior authorization is required for initial treatment
Documentation must include clinical historyDocumentation must include clinical history
+ 1 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

CPT, HCPCS, and ICD-10 Codes for Drug Abuse Treatment Under NCD 28

NCD 28 does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is not an oversight — it's a deliberate policy structure that pushes code-level coverage decisions to the MAC level.

That creates real exposure for your billing team. Without NCD-specified codes, your claims are evaluated against MAC-level local coverage determinations and accepted medical practice standards. A claim that would pass under one MAC's LCD might fail under another's.

What this means for drug abuse treatment billing:

The lack of a code list in NCD 28 is not a green light to bill anything adjacent to substance abuse treatment. It's an instruction to look at your MAC.


Get the Full Picture

Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.

🔍 Search by any code 🔔 Real-time alerts 📊 Line-by-line diffs ⏰ Deadline tracking
Get Full Access → $99/mo · 14-day money-back guarantee